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Abstract Oral symptoms are among the most distressing
manifestations for patients with Sjögren’s syndrome (SS).
The feeling of dry mouth is unpleasant, and hyposalivation
may contribute to difficulty in speaking, chewing and
swallowing and reduced quality of life. Reduced salivary flow
increases the risk for dental caries and problems with prosthet-
ic replacement. It seems that SS is not as frequently occurring
as previously anticipated. Population-based prevalence stud-
ies on primary SS in Europe, conducted on large background
populations and in accordance with the AECG criteria, report-
ed of a prevalence of 1–9 cases per 10,000 people. This gives
a combined prevalence of nearly 39/100,000 (~0.04 %). The
cause of Sjögren’s syndrome is even now not fully under-
stood, and the treatment of oral symptoms is still mostly pal-
liative. Hopefully, useful information will appear from the
new methods that are now available for genome wide associ-
ation studies, epigenetics, DNA methylation studies, and pro-
teomics. Similarly, this is anticipated for the immunological
side of the story. The interferon signature, the interferon
γ/interferon α mRNA ratio, and CXCL13 are among the pro-
posed biomarkers of active disease. In this review, we provide
an update on oral aspects of Sjögren’s syndrome with empha-
sis on the latest publications on these topics.
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Epidemiology of Sjögren’s Syndrome
Sjögren’s syndrome (SS) is a complex autoimmune disease
characterized by a broad spectrum of clinical and serological
manifestations. Patients with SS experience immune-
mediated destruction of salivary and lacrimal glands leading
to reduced lacrimal and salivary flow. Dry eyes and dry mouth
together with fatigue are among the most common complaints
[1, 2]. Extraglandular manifestations, such as involvement of
the peripheral nervous, pulmonary, or gastrointestinal system,
kidney, skin, myalgias, and arthralgias are frequently seen
leading to reduced quality of life [3]. A range of autoanti-
bodies can be present in Sjögren’s syndrome such as anti-
SSA/Ro (Sjögren’s syndrome autoantigen A) and anti-SSB/
La (Sjögren’s syndrome autoantigen B) antibodies, rheuma-
toid factor, cryoglobulins, and antinuclear antibodies. Patients
with primary SS also have an increased risk of B cell lympho-
mas [4]. If the disease occurs together with another autoim-
mune disease such as for instance rheumatoid arthritis or sys-
temic lupus erythematosus, its designation is secondary SS.
During the past decade, the 2002 revised American
European Consensus Group (AECG) classification criteria
have been widely used in studies of SS [5]. Recently,
American College of Rheumatology (ACR) proposed a new
set of criteria based on objective tests [6]. Great concordance
was experienced between these two sets of criteria [7•].
However, a discrepancy between clinical diagnosis and
criteria was experienced by both sets of criteria [8]. To assess
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the extraglandular systemic manifestations, the European
League Against Rheumatism (EULAR) promoted and sup-
ported an international collaborative study (the EULAR-SS
Task Force) aimed at developing consensual disease activity
indexes in SS [3]. This resulted in two indexes, the EULAR
SS Disease Activity Index (ESSDAI) and the EULAR
Sjögren’s Syndrome Patient Reported Index (ESSPRI). The
ESSDAI provides a standardized instrument for the homoge-
neous evaluation of systemic activity in clinical trials and dai-
ly practice, and includes organ-by-organ definitions.
Hopefully, this will provide the basis for further development
of evidence-based diagnostic and therapeutic guidelines [3].
The ESSPRI assesses the patient’s symptoms. Very recently,
ClinESSDAI was developed, which is a clinical score without
biological domain, meant as a tool for biological studies
which provides an accurate evaluation of disease activity in-
dependent of B-cell biomarkers [9].
Numerous classification criteria for pSS have been pro-
posed, but the most widely used are the AECG criteria. To
accurately estimate the prevalence in Europe, we have to focus
on robust studies using good methodology and large back-
ground population. To estimate the prevalence of pSS in
Europe, Cornec and Chiche [10] appointed three population-
based studies which had used the AECG classification criteria,
which were based on large background populations, and which
had used effective case-finding methods [1112•, 13•]. A preva-
lence of 1–9 cases per 10,000 people was found, which gave a
combined prevalence of nearly 39/100,000 (~0.04 %), which is
far lower than previously reported (up to 6%) [10]. In Europe, a
disease is considered rare when it affects less than one person
per 2000, and pSS may thus be regarded as a rare disease.
Table 1 gives an overview of some prevalence studies of
pSS in Europe. Of note, although the Maldini et al.’s French
study [13•] is based on a sample survey estimating popula-
tion ≥ 15 years old, this study gives the lowest prevalence
figure by using the AECG criteria [5]. The study by
Kabasakal et al. [14] was based on a female population which
may contribute to the higher prevalence. The estimate of point
prevalence of pSS in both sexes was 0.15%, and in the female
population 0.29 % in the study by Trontzas and Andrianakos
[15]. More data especially from non-European locations are
warranted to definitively describe the epidemiological aspects
of SS.
Dry Mouth and Saliva
Xerostomia refer to the subjective feeling of dry mouth and
can present in people with normal saliva secretion.
Hyposalivation can be objectively measured and typically is
below 0.1 mL/min [16]. The condition can be either tempo-
rary or chronic and can be caused by a range of factors of
which the most common is xerogenic medications. Other rea-
sons may be radiation and chemotherapy for head and neck
cancers, hormone disorders, infections, or systemic autoim-
mune diseases such as SS.
Patients with xerostomia suffer not only from reduced
quantity of saliva but also a reduced quality [17].Whole saliva
consists of two main components, serous and mucous, in ad-
dition to hundreds of other substances such as a great diversity
of minerals, antibodies, glycoproteins, bacteria, and complex
mixes of proteins, lipids and ions a.o. Saliva has many impor-
tant functions. Salivary mucins act as a lubricating agent and
create a protective layer on teeth and mucosa. Mucins coat
ingested food particles allowing them to be smoothly
swallowed. The antibacterial, antifungal, and antiviral agents
in saliva regulate the oral flora and help to prevent oral infec-
tions [18].
Prolonged dry mouth may result in functional alterations,
such as difficulty in speaking, chewing, and swallowing, and
in wearing dental prosthesis [19]. Other consequences are the
increased plaque accumulation, increased risk of dental caries
and erosions, and symptoms in the mucous membranes, lips
and tongue, angular cheilitis and reduced quality of life. As the
saliva volume decreases, the concentrations of IgA,
lactoferrin, salivary proteins and peptides also are diminished,
Table 1 Prevalence studies on primary Sjögren’s syndrome in Europe according to the AECG criteria
Author Publication year Country Population size Criteria Prevalence %
(95 % CI)
Trontzas & Andrianakos [15] 2005 Greece 8740 AECG 0.15 (0.09–0.21)
Alamanos et al. [11] 2006 Greece 488,435 AECG 0.09 (0.08–0.1)b
Kabasakal et al. [14] 2006 Turkey 831 AECG 0.72 (0.33–1.57)a
Birlik et al. [97] 2009 Turkey 2835 AECG 0.21 (0.03–0.29)
Anagnostopoulos et al. [98] 2010 Greece 3528 AECG 0.23 (0.22–0.75)
Göransson et al. [12•] 2011 Norway 852,342 AECG 0.05 (0.048–0.052)b
Maldini et al. [13•] 2014 France 1,172,482 AECG 0.01 (0.01–0.02)b
a The prevalence of pSS in the study of Kabasakal et al. was based on a female population only
b Population-based studies conducted on a large background population
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and the susceptibility to Candida infections increases.
Comorbid medical conditions and medication use may have
substantial impact on oral symptoms in individuals with SS [20].
Dental Caries and Periodontal Disease
Reduced salivary flow and changes in saliva composition make
patients at a greater risk for development of dental caries. The
important buffer and remineralization capacities are reduced, as
well as the protective effect against microorganisms.
A higher number of decayed, missed, and filled tooth sur-
faces (DMFS) and teeth (DMFT) has been demonstrated in SS
patients compared to healthy controls [21, 22], and caries may
emerge at more unusual localizations such as on incisal, labial
and root surfaces [23]. DMFS has been found inversely cor-
related to salivary flow rates [21].
Patients with SS harbor higher numbers of cariogenic and
acidophilic micro-organisms such as Streptococcus mutans
and Lactobacillus species than healthy control individuals
[21].
Compared with individuals with subjective sicca com-
plaints [24], SS patients have a higher plaque index, gingival
index, papillary bleeding index, and DMFT. Others found no
significant differences in DMFTwhen comparing SS patients
with patients with xerostomia or other immune diseases [25].
The difference in DMFT score has by some been ascribed to
the missing tooth component, but often the reasons for extrac-
tion are not known or reported, if it has been conducted be-
cause of caries or attachment loss [21, 24]. However, SS does
not seem to contribute to more periodontal disease than is
found in healthy individuals, although the reports are some-
what conflicting [24–29]. It should be noted that the studies in
general have included few patients.
Dental Implants
Patients with SS often suffer from a high incidence of caries as
a consequence of reduced saliva production. This may result
in the need of prosthetic replacements. In cases with wide-
spread loss of teeth, when there was not enough dental support
for conventional fixed prosthesis, the only treatment available
in the past was complete or partial dentures. Considering the
problems with dry mouth, patients with SS have great diffi-
culties with wearing partial dentures, and even worse, full
dentures. In the absence of the lubricating effect of saliva,
the oral mucosa is prone to sores and chafing from the dental
prosthesis. The retention of full dentures in edentulous jaws
becomes inadequate, which often leads to problems with
speech and eating and impaired health-related quality of life.
In view of this, dental implant rehabilitation as an alternative
treatment is of special interest.
Implant survival rates of dental implants in healthy individ-
uals over a 10-year period are high, from around 93–97% [30,
31]. However, peri-implant mucositis are quite common, and
peri-implantitis is a challenge, reported by some to range be-
tween 10% at an implant level and 20% at a patient level [31].
A history of periodontitis influences the success negatively,
even if the patients have been treated. The type and severity of
the disease also seem to be of importance for future events.
Patients with aggressive periodontitis exhibit decreased im-
plant success and survival rates when compared with chronic
periodontitis patients, and if compared with a non-
periodontitis group, they have a higher incidence of peri-
implantitis and bone loss [31].
Sowhat is the prognosis for dental implants in patients with
SS? These patients present with mucosal dryness and experi-
ence reduced protection by saliva and a higher plaque index,
which could mean a difference [24]. Despite this, as already
mentioned, it seems that this group of patients does not have
more periodontal disease than systemically healthy individ-
uals. Will they experience more peri-implantitis?
The number of studies on dental implants in SS is scarce
and even more limited with regard to follow-up time. There
are a few publications based on single case reports (for review
see [32]) . As an example, Binon et al. [33] presented a case
report with mandibular osseointegrated implants with a fixed
complete denture remaining stable and functional during
13 years follow-up. Isidor et al. [34] reported of 84 % success
rate after 4-year follow-up of 54 implants in 8 patients, while
Payne et al. [35] achieved 88.4 % success rate of 26 implants
placed in three patients but with only 2-year follow-up. A
more recent publication examining 50 patients with SS found
a prevalence of peri-implantitis of 14 % of the patients (11 %
of the implants), which is similar to what is reported for sys-
temically healthy individuals [36]. With a median follow-up
of 46 months, the implant survival was 97 %; of the 142
implants inserted, four implants in two patients were lost.
They also reported that oral functioning correlated negatively
with oral dryness and chewing ability in these patients. These
results were in line with a patient-reported investigation on
outcomes of dental implants in 32 patients with SS. A total
of 5 of 104 (4.8 %) implants had to be removed over a mean
period of 4.9 years in the patients [37]. In summary, based on
the available studies, implant survival rates in patients with SS
seem to be comparable to those in systemically healthy indi-
viduals [38].
Pathogenesis
Salivary Gland Biopsy—Diagnostic Tool
In experienced hands, minor salivary gland biopsy is a well-
tolerated procedure associated with a low complication rate
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[39]. While some patients are willing to have three or even
four biopsies removed for the purposes of follow up and re-
search, there is an ethical limit on the number of consecutive
lip biopsies.
Salivary gland involvement has a central role when
assessing the development and pathogenesis of SS. Notably,
SS histopathology is strongly associated with autoantibodies
but only correlates weakly with xerostomia in SS patients. The
diagnostic role of salivary gland histology still remains widely
accepted and a central part of both AECG and the new pro-
posed classification criteria endorsed by the ACR in 2012 [6].
The autoantibodies Ro/SSA and La/SSB are valuable diag-
nostic tools, they appear early in the disease, persist, and cor-
relate with focus scores. Histological focus scoring has been
employed to describe salivary gland involvement in SS, where
a positive biopsy with mononuclear cell infiltrates comprising
of ≥50 mononuclear cells per 4 mm2 results in a positive score
value of 1–12 according to numbers of foci seen.
Few studies have assessed other histopathological features
in the salivary gland environment and their possible associa-
tions with diagnosis and stage of disease. The destruction of
salivary gland tissue in SS is commonly accompanied by the
development of adipose tissue and fibrosis where adipocytes
can occupy a large part of the gland. A recent study [40] high-
lights the possibility that there could be a relationship between
the disease activity and adipose tissue replacement in the
gland, and that fat replacement could be a helpful support in
the diagnostic evaluation of the glandular tissue. Furthermore,
a possible active role of adipocytes in the immune reactions in
the glandular environment has been suggested [40, 41]. During
the last years, novel diagnostic tools have been investigated.
These would include salivary gland ultrasound imaging where
parenchymal inhomogeneity appears to be the method with
most promising results [42]. Even if its role in the early stages
of disease is debated, it is worthy of note that, when used in
association with traditional tests, ultrasound improves the
diagnostic sensitivity of the AECG [43–46].
Proteomic biomarker profiles of unstimulated whole saliva
from SS patients have been investigated for potential as a tool
for patient subclassification [47]. Further studies will be nec-
essary to determine the utility of such an approach. To facili-
tate the evaluation of treatment efficacy in clinical trials and to
select subgroup of patients for personalized treatment, the
availability of new prognostic markers is needed.
Immunopathology—Cellular Populations
The classic glandular lesion is composed of a lymphoid infil-
trate of T and B lymphocytes, whose distribution may vary
according to disease severity. Macrophages, plasma cells, NK
cells, and dendritic cells are also present in varying degree [48,
49]. A great effort has been made to in deeply characterizing
the role of different T cell subsets in pSS. In pSS patients, the
specific T helper subset, Th 17 cells, mainly defined by secre-
tion of cytokine IL-17, has been found in elevated numbers
both in the periphery and also present in the salivary gland
tissue [50, 51]. The follicular T helper cells are another subset
derived from naïve lymphocytes under the stimulus of IL-12
secreted by dendritic cells, and these cells are involved in the
crosstalk between T and B cells. It has been indicated that
these cells participate in the pathogenesis of pSS by promoting
B-cell maturation [52].
B cell hyperactivity represents a key hallmark in the path-
ogenesis of SS and hypergammaglobulinemia, autoantibody
production and alterations of B cell subpopulations are dis-
tinctive features of pSS patients. Patients with pSS present up
to 16 times increased risk for developing non-Hodgkins lym-
phoma (NHL) [4] and mucosa associated lymphoid tissue
(MALT) lymphoma in the salivary glands and gastrointestinal
tract compared to healthy individuals. Lymphoid organization
in the form of germinal center (GC)-like structures has been
identified in the salivary glands of a subgroup of SS patients
[53]. Notably, the identification of germinal center-like struc-
tures has been suggested to be a possible predictor of the
development of lymphoma since, based on results from a
study from Theander et al., the majority of the GC+ patients
developed lymphoma later on [54]. This novel finding may
allow identification of high-risk patients for repeated lympho-
ma screening and selection of candidates for advanced B-cell
directed biological treatment.
Negative status for anti-Ro/SSA and/or anti-La/SSB is sug-
gested to be a protective factor for evolution toward lympho-
ma in these patients [55]. However, the development of lym-
phomas in pSS is not confined only to serologically positive
patients for anti-Ro and anti-La. Accordingly, the rheumatol-
ogists are encouraged to include the minor salivary gland bi-
opsy in the routine work-up [54]. CD4+ T lymphocytopenia is
an additional strong risk factor for developing lymphoma [4].
Lymphomas often develop in salivary glands of SS patients
where the disease is active. Nocturne and Mariette recently
launched a B2014 proposed scenario for the pathophysiology
of pSS-associated lymphoma^ [56]. They envisioned that im-
mune complexes with antibodies against specific antigens
such as SSA/Ro and SSB/La or others, continuously stimulate
autoimmune B cells containing rheumatoid factor activity.
Furthermore, that defects in control of NF-kB activation ac-
centuate B cell over-activation and promote survival of B cells
and oncogenic mutations.
Genetics
The HLA carries the major genetic influence on susceptibility
to autoimmune diseases, as it is an important key in antigen
presentation and immune response. A meta-analysis found
DRB1*03:01, DQA1*05:01, DQB1*02.01, and DRB1*03
to be risk factors for pSS while DQA1*02:01, DQA1*03:01,
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and DQB1*05:01 alleles were protective [57]. DRB1*03-
DQB1*02 was the significant risk haplotype associated with
pSS on a worldwide level in that study. This is in line with our
previous study where we also found components of the
DRB1*03-DQB1*02-DQA1*0501 haplotype as the strongest
contributors to the formation of an anti-Ro/La response in a
study of pSS Caucasions [58].
Several non-HLA regions have been implicated in pSS.
Gene expression microarray studies on labial salivary glands
and peripheral blood showed dysregulation of type I
interferon-inducible genes [59, 60]. Two GWAS studies have
recently been performed on pSS, one on European descents,
and one on Chinese descents [61••, 62••]. Among SS-
associated non-HLA genes discovered by GWAS, we find
STAT4 and IRF5 encoding transcription factors, BLK coding
for B cell kinase, as well as genes encoding the IL-12A cyto-
kine, and interestingly, genes involved in NF-kB signaling and
the CXCR5 chemokine production [63]. CXCR5 is receptor
of CXCL13, which directs B cells to lymphoid follicles [64].
Mice deficient of Cxcl13 or its receptor Cxcr5 fail to form
these structures [64, 65]. In addition to the interferon signature
appearing from the microarray gene expression profiling of
minor salivary glands of primary SS patients and healthy con-
trols, particularly two other interesting observations were
made by Hjelmervik et al. [59]. Firstly, CXCL13 which di-
rects B cells chemotaxis was differently expressed in patients
and controls. CXCL13 were among the genes that were
expressed in 9 of 10 patients with pSS, whereas it was only
expressed in 1 of 10 healthy individuals [59]. This is support-
ed by a recent study by Kramer et al. who found CXCL13 to
be elevated in serum and saliva of SS patient and in mice
models [66]. Secondly, we found lymphotoxin-β (LTB) to
be among the most highly expressed genes in inflamed sali-
vary glands of pSS patients. Lymphotoxin-β receptor (LTβR)
signaling is crucial for the formation of lymphoid tissue, and
LTβ can activate NF-kB pathways that promote inflammation
[67–69]. When we in a later experiment blocked the Ltβr in
animal models of SS, there was an increase in salivary secre-
tion and a reduction of inflammation in the glands [70]. We
experienced an amelioration of SS after neutralization of Ltβr
signaling. A congenic mouse model was also developed that
differed genotypically from the control mice only in two non-
MHC loci, which were sufficient for the congenic mice to
develop sialadenitis spontaneously [71]. Cxcl13 and Ltβ were
among the genes that were found differentially expressed in
salivary glands of the NOD congenic mice compared to con-
trol mice. Furthermore, Ltβ blockade also reduced Cxcl13 in
lacrimal glands of a NOD model of SS improving the corneal
integrity [72, 73]. Recently, early BAFF receptor blockade
was shown to mitigate murine SS [74•]. Concomitant
targeting of CXCL13 and BAFF receptors prevented salivary
hypofunction [74•]. CXCL13 has been proposed as a bio-
marker for SS and a possible therapeutic target [66].
Epigenetic factors such as altered patterns of DNA meth-
ylation have been implicated in models of autoimmune dis-
ease. Recent studies have reported epigenetic alterations such
as changes in DNA methylation, histone modification, micro-
RNA expression, and have found defective DNA methylation
to be associated with SSB gene expression and lymphocyte
infiltration in pSS [75–77]. Just recently, a genome-wide
DNA methylation study on human labial salivary glands of
SS was presented [78]. Several genes and pathways previous-
ly thought to be involved in disease-related processes as well
as a number of new candidates were discovered. Interestingly,
a correlation was recognized between DNAmethylation and a
set of genes previously found highly differentially expressed
in pSS and healthy salivary glands [59, 78]. Furthermore,
genome-wide DNA methylation profiles showed prominent
hypomethylation of interferon-regulated genes in whole blood
and CD19+ cells in pSS [79•].
As mentioned, increased expression of type I interferon-
regulated genes have been demonstrated in autoimmune dis-
eases [80]. An interferon signature was demonstrated in sera
and minor salivary glands of pSS [59, 81], and in CD14
monocytes of pSS patients it was found associated with dis-
ease activity and higher B cell activation factor (BAFF) gene
expression [82]. CXCL10 is one of the most strongly upregu-
lated type I interferon-regulated genes and was found upreg-
ulated in salivary glands of pSS patients [59, 80]. A causal
relationship between type I interferon production and devel-
opment of autoimmune disease has been suggested, and as a
biomarker of active disease, the interferon signature is an in-
teresting target for research aiming at new treatment possibil-
ities [80]. The contribution of type I and type II interferon
signatures to SS pathogenesis and lymphomagenesis was re-
cently investigated, and interferon γ/interferon αmRNA ratio
was proposed as a novel biomarker for prediction of in situ
lymphoma development in SS [83].
Type I interferons are involved in innate immune response
against viral infection and help to regulate the activity of the
immune system. A link between the LTβR and interferon
pathways and mouse models has pointed to the pathogenic
role of the lymphotoxin and interferon I pathways in human
autoimmune diseases [69]. The lymphotoxin pathway has a
role in orchestrating the development of homeostasis of lymph
nodes through regulation of homeostatic chemokines, and the
LTβR signaling is essential in differentiating stromal cells and
macrophages in lymphoid organs to produce interferon I in
response to virus infection. A possible potential of the
lymphotoxin network as a tool for treatment of autoimmune
diseases has been suggested [69].
Virus has been suggested as one of the environmental fac-
tors that could trigger SS and be involved in SS pathogenesis,
and the observation that infection can precipitate autoimmune
abnormality is not new [84]. A number of candidates have
been suspected to trigger such a disease, such as human herpes
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virus 6 (HHV6), cytomegalovirus (CMV), Epstein-Barr virus
(EBV), hepatitis C virus (HCV), human T lymphotropic virus
type 1 (HTLV-I), and human immunodeficiency viruses (HIV)
[85]. However, the connection is not clear, and more studies
are justified.
Autoimmune diseases aggregate in families. In a
population-based family study of 105 Taiwan patients with
SS who had an affected first-degree relative, Kuo et al. [86]
found a relative risk (RR) for SS in siblings of patients with SS
to be 18.99, 11.31 in offspring, and 12.46 in parents. In first-
degree relatives of SS patients the RR were 6.25 for having
systemic lupus erythematosus, 3.38 for multiple sclerosis and
2.95 for rheumatoid arthritis [86].
Treatment
Intervention for Dry Mouth
Often dry mouth cannot be cured, but there are ways to de-
crease the dry mouth symptoms and improve the feeling of
dry mouth, at least temporarily. Not at least, it is mandatory to
implement measures to reduce caries risk in patients with
hyposalivation.
Some patients feel that palliative treatment with salivary
substitutes, chewing gum and sugarfree lozenges help to some
extent, but the effect is short-lived. The symptomatic and sup-
portive treatment of dry mouth can be either local or systemic
[87]. Sugar-free gum, mint, and lozenges are recommended
for salivary stimulation. Effort has been made to produce ar-
tificial saliva which mimics the normal and protective effects
of saliva, with addition of a.o. remineralizising and antimicro-
bial agents. The effect of topical treatments in reducing symp-
toms of dry mouth was recently the topic of a Cochrane data-
base systemic review [16]. Sprays, lozenges, mouthrinses,
gels, oils, chewing gum, and toothpastes were evaluated in
this review; however, there was no strong evidence that any
topical treatment was effective for relieving the sensation of
dry mouth. An oxygenated glycerol triester saliva substitute
spray was more effective than a water-based electrolyte spray.
Chewing gum increased saliva production, but there was no
evidence that gum was better or worse than saliva substitutes.
A very important supplement in pat ients with
hyposalivation is the use of fluoride to decrease tooth decay.
Daily use of fluoridated dentifrice and fluoride rinse is neces-
sary remineralization options. Fluoride gel in mouth guard is
an alternative in serious cases. Toothpaste with sodium lauryl
sulfate and acidic products and those containing sugar should
be avoided [88, 89].
Prophylaxis, more frequent dental visits with professional
cleaning, oral hygiene instructions and motivation should be
accomplished, including application of topical fluoride gel
when indicated. More detailed treatment strategies for
xerostomia, and overview of salivary stimulators, oral mois-
turizers, and salivary substitutes can be found in recent pub-
lished comprehensive reviews [87, 90].
SS patients are prone to fungal infection. Antifungal rinses
or lozenges are available for treatment of oral candidiasis. If
patients have removable prostheses, the prostheses may be
soaked in for instance a chlorhexidine solution. One must be
aware of the discoloration this procedure could cause.
Physiological and Pharmacological Stimulation and Gene
Therapy
There is insufficient evidence to determine the effects of
electrostimulation devices on dry mouth symptoms or saliva
production in SS [91]. Similarly, any better effect of acupunc-
ture compared to placebo has been difficult to prove.
Insufficient number of patients makes it difficult to conclude.
The muscarinic receptor agonists pilocarpine and
civemeline may have good effect in stimulating to increased
salivary secretion [92]. Pilocarpine was associated with im-
provements in dry mouth of 61–70 vs. 24–31 % in placebo,
whereas civemeline was associated with improvement in dry
mouth of 66–76 vs. 35–37 % in placebo [88]. Some regard
pilocarpine as the best-performing sialagogues drug for SS
[93].
There has been an interest in salivary glands as delivery
organs for gene therapy. The glands have several advantages
in that respect, being easily accessible, well encapsulated, and
non-critical for life organs with extraordinary secretory abili-
ties, and producing proteins for transport in exocrine and en-
docrine directions [94]. Salivary gland gene transfer is easily
accomplished and can be done in a non-invasive manner [95].
In 2003, the first publication was released showing transfer of
a gene encoding immunomodulatory protein resulting in im-
proved salivary gland function andmorphology in a SSmouse
model [96]. To be used for treatment in SS, however, gene
therapeutics seems yet far away, also because of our lack of
complete understanding of the disease process.
Summary
In this review, we have focused on the most recent literature
on SS epidemiology from an oral perspective, including some
references giving necessary background for the discussion of
the topics. To be updated on the most recent literature regard-
ing pathogenesis, genetic aspects, clinical and basic features,
and treatment of SS in general, we refer to the review from
Ferro et al. [7•].
It is clear that the SS may entail serious oral problems of
importance for quality of life in addition to impaired systemic
health condition. More research is needed to understand the
disease pathogenesis and to identify the initiating factor (s) of
Curr Oral Health Rep (2016) 3:328–336 333
SS, to be able to perform early diagnostics and improve the
treatment of the disease.
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